{"nctId":"NCT01026194","briefTitle":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","startDateStruct":{"date":"2009-12"},"conditions":["Type 2 Diabetes Mellitus"],"count":204,"armGroups":[{"label":"Placebo / Teneli + Pio","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo / Teneli (Teneligliptin) + pio (pioglitazone)"]},{"label":"Teneli / Teneli + pio","type":"EXPERIMENTAL","interventionNames":["Drug: Teneli / Teneli + pio"]}],"interventions":[{"name":"Placebo / Teneli (Teneligliptin) + pio (pioglitazone)","otherNames":[]},{"name":"Teneli / Teneli + pio","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who are 20 - 75 years old\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug\n* Patients whose HbA1c is between 6.5% and 10.0%\n* Patients who took Thiazolidinedione for diabetes over 16 weeks before administration of investigational drug\n* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)\n* Patients who are accepting treatments of arrhythmias\n* Patients with serious diabetic complications\n* Patients who are the excessive alcohol addicts\n* Patients with severe hepatic disorder or severe renal disorder.\n* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 12","description":"The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.05"},{"groupId":"OG001","value":"-0.94","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 12","description":"The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"2.0"},{"groupId":"OG001","value":"-21.0","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12","description":"The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.722","spread":"5.134"},{"groupId":"OG001","value":"-85.031","spread":"5.134"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12","description":"The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"3.6"},{"groupId":"OG001","value":"-56.9","spread":"3.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Glucose urine present","Blood urine present","Blood creatine phosphokinase increased"]}}}